Acute intermittent porphyria

What is Acute intermittent porphyria?

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the body’s ability to produce heme, a vital component of hemoglobin and other proteins. The condition is caused by a deficiency in the enzyme hydroxymethylbilane synthase (HMBS), leading to the accumulation of toxic substances called porphyrins and their precursors. AIP affects approximately 1 in 75,000 people, though symptomatic cases are much rarer, as many carriers never develop symptoms. The disorder can cause severe, life-threatening attacks involving excruciating abdominal pain, neurological symptoms, and other serious complications.

Key statistics

Symptoms

The hallmark symptoms include severe abdominal pain, rapid heart rate (tachycardia), low sodium levels (hyponatremia), port-wine colored urine, and episodic attacks.

During acute attacks, patients experience excruciating abdominal pain that can last for days or weeks. The pain is typically cramping or colicky and may be accompanied by nausea, vomiting, and constipation. Neurological symptoms are common and can include muscle weakness, particularly in the arms and legs, sensory disturbances, and in severe cases, paralysis. Mental health symptoms such as anxiety, depression, confusion, hallucinations, and seizures may occur during attacks.

Cardiovascular symptoms include rapid heart rate and high blood pressure. The characteristic dark red or purple urine (port-wine colored) occurs due to elevated porphyrin levels, though this may not be present in all attacks. Between attacks, many patients experience chronic symptoms including fatigue, muscle pain, and neurological complications that may persist.

Submit Your Paper

Causes and risk factors

AIP is caused by mutations in the HMBS gene, which provides instructions for making the enzyme hydroxymethylbilane synthase. This enzyme is essential for heme production, and its deficiency leads to the accumulation of toxic porphyrin precursors. The condition follows an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene is needed to cause the disorder.

However, having the genetic mutation does not guarantee symptoms will develop. Many carriers remain asymptomatic throughout their lives. Attack triggers include certain medications (particularly those that induce cytochrome P450 enzymes), hormonal changes (menstruation, pregnancy, hormone replacement therapy), alcohol consumption, fasting or low-calorie diets, infections, stress, and exposure to certain chemicals or toxins. Women are more likely to experience symptomatic attacks, particularly related to hormonal fluctuations.

Prevention

As AIP is a genetic condition, primary prevention is not possible. However, attack prevention is crucial for diagnosed patients. This involves avoiding known triggers such as unsafe medications, maintaining regular eating patterns, managing stress, and avoiding excessive alcohol consumption.

Genetic counseling is essential for families affected by AIP, as each child of an affected parent has a 50% chance of inheriting the mutation. Carrier testing and genetic testing are available for family members. Prenatal testing is possible but rarely pursued due to the variable expression of the condition and the fact that many carriers never develop symptoms.

Complications

Untreated acute attacks can lead to severe, life-threatening complications. Neurological complications may include respiratory paralysis requiring mechanical ventilation, seizures, and permanent nerve damage. Cardiovascular complications can include severe hypertension and arrhythmias.

Long-term complications may include chronic kidney disease, liver problems including an increased risk of hepatocellular carcinoma, persistent neurological deficits, chronic pain syndromes, and mental health disorders. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) can cause dangerous electrolyte imbalances. Without proper management, mortality during severe attacks can be significant.

Diagnosis

Diagnosis of AIP requires a combination of clinical suspicion, biochemical testing, and genetic analysis. During acute attacks, urine levels of porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) are markedly elevated. The Watson-Schwartz test or Hoesch test can provide rapid screening for elevated PBG.

Enzyme activity testing measures HMBS activity in red blood cells, which is typically reduced to about 50% of normal levels. However, enzyme levels can overlap with normal ranges in some carriers. Genetic testing for HMBS mutations provides definitive diagnosis and is essential for family screening.

Additional tests during attacks may show hyponatremia, elevated liver enzymes, and increased white blood cell count. Neurological testing including nerve conduction studies may reveal peripheral neuropathy. Imaging studies are typically normal but may be needed to exclude other causes of abdominal pain.

Treatment

Treatment focuses on managing acute attacks and preventing future episodes. For acute attacks, hemin (hematin) remains a cornerstone therapy, administered intravenously to suppress the overproduction of porphyrin precursors. Pain management often requires opioid analgesics due to the severity of symptoms.

Givosiran, an RNA interference therapy, was approved for preventing attacks in adults with AIP. This monthly subcutaneous injection significantly reduces attack frequency and the need for hemin treatment. Supportive care includes careful fluid and electrolyte management, treatment of hyponatremia, and management of cardiovascular symptoms.

Glucose administration can help suppress the heme biosynthetic pathway during attacks. Safe medications must be used, as many common drugs can precipitate attacks. Comprehensive medication lists are maintained by porphyria organizations to guide safe prescribing.

Prognosis

The prognosis for AIP varies significantly depending on attack frequency, severity, and access to appropriate treatment. Many individuals with the genetic mutation never develop symptoms and have a normal life expectancy. For those who do experience attacks, early diagnosis and proper management can prevent most serious complications.

With modern treatment including hemin and givosiran, the mortality rate during acute attacks has decreased substantially. However, some patients may develop chronic complications including persistent neurological deficits, chronic kidney disease, or liver problems. Quality of life can be significantly impacted by recurrent attacks, chronic pain, and the anxiety of potential future episodes.

Quality of life

Living with AIP requires careful lifestyle management and ongoing vigilance. Patients must maintain regular eating patterns, avoiding fasting or extreme dieting. Stress management techniques, regular sleep schedules, and moderate exercise can help prevent attacks. Many patients benefit from working with dietitians familiar with porphyria.

Mental health support is crucial, as the unpredictable nature of attacks can cause significant anxiety and depression. Support groups and patient organizations provide valuable resources and community. Career considerations may be necessary, as frequent hospitalizations during attacks can impact work attendance. Emergency action plans and medical alert identification are essential for patients experiencing recurrent attacks.

Pregnancy and fertility

Pregnancy can be challenging for women with AIP, as hormonal changes may trigger attacks. However, many women successfully carry pregnancies to term with careful monitoring and management. Preconception counseling is essential to optimize care and discuss genetic risks.

During pregnancy, safe medication options are limited, and hemin may be used cautiously if attacks occur. Close collaboration between hematologists, obstetricians, and other specialists is crucial. Each child has a 50% chance of inheriting the HMBS mutation, making genetic counseling an important part of family planning discussions.

Children

AIP rarely presents before puberty, as hormonal changes often trigger the first symptoms. When it does occur in children, attacks may be less typical and diagnosis can be delayed. Genetic testing can identify carriers among family members, but routine testing of asymptomatic children is controversial due to the variable expression of the condition.

Education about trigger avoidance becomes important as children reach adolescence. Pediatric hematologists experienced with porphyrias should manage children with confirmed or suspected AIP.

When to see a doctor

Immediate medical attention is needed for severe abdominal pain, especially when accompanied by neurological symptoms like muscle weakness, confusion, or difficulty breathing. Rapid heart rate, seizures, or dark-colored urine should prompt urgent evaluation.

Routine care should be sought for family history of porphyria, recurrent unexplained abdominal pain, or when planning pregnancy in known carriers. Regular monitoring is essential for diagnosed patients, even between attacks.

Regional context

While AIP occurs worldwide, certain populations have higher prevalence rates due to founder effects. Some regions of Northern Europe, particularly Scandinavia, report higher frequencies. Limited data exists for the Caucasus region specifically. We invite medical professionals from Georgia, Armenia, and Azerbaijan to contribute regional epidemiological data to expand our understanding of AIP prevalence in these populations.

Research and clinical trials

Current research focuses on novel therapies, including gene therapy approaches and additional RNA interference treatments. Studies are investigating biomarkers for predicting attacks and monitoring treatment response. Liver transplantation is being explored for severe, refractory cases.

Clinical trials are ongoing for new preventive therapies and improved formulations of existing treatments. Patients can search for relevant trials at ClinicalTrials.gov using the terms “acute intermittent porphyria” or “AIP.” Natural history studies are also providing valuable insights into disease progression and outcomes.

Frequently asked questions

Can I live a normal life with AIP?

Many people with AIP gene mutations never develop symptoms and live completely normal lives. Even those who do experience attacks can often manage them effectively with proper treatment and trigger avoidance.

Is AIP hereditary?

Yes, AIP follows autosomal dominant inheritance. Each child of an affected parent has a 50% chance of inheriting the gene mutation, though not everyone who inherits it will develop symptoms.

What medications should I avoid?

Many medications can trigger AIP attacks. The American Porphyria Foundation maintains comprehensive lists of safe and unsafe medications. Always inform healthcare providers about your AIP diagnosis before receiving any new medication.

Can stress trigger an attack?

Yes, physical and emotional stress can trigger AIP attacks. Stress management techniques, adequate sleep, and maintaining regular routines can help reduce attack risk.

Is there a cure for AIP?

Currently, there is no cure for AIP, but treatments like givosiran can significantly reduce attack frequency, and hemin can treat acute episodes effectively. Research into gene therapy and other curative approaches continues.

Support and resources

• American Porphyria Foundation – Comprehensive resources and support
• Orphanet – Rare disease information portal
• National Organization for Rare Disorders (NORD)
• EURORDIS – European rare disease organization
• World Health Organization (WHO) – Global health information

Related conditions

• Hereditary coproporphyria
• Variegate porphyria
• Porphyria cutanea tarda
• Erythropoietic protoporphyria
• Hereditary tyrosinemia type I

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.